Epoch Investment Partners Inc. lowered its position in shares of Colgate-Palmolive (NYSE:CL) by 5.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 191,530 shares of the company’s stock after selling 12,087 shares during the period. Epoch Investment Partners Inc.’s holdings in Colgate-Palmolive were worth $11,400,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of CL. BlackRock Inc. raised its stake in Colgate-Palmolive by 13.5% in the fourth quarter. BlackRock Inc. now owns 60,648,605 shares of the company’s stock valued at $3,609,804,000 after purchasing an additional 7,236,342 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in Colgate-Palmolive by 5,779.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,625,533 shares of the company’s stock valued at $95,000 after purchasing an additional 5,529,852 shares in the last quarter. Ceredex Value Advisors LLC acquired a new position in Colgate-Palmolive in the fourth quarter valued at about $71,576,000. Los Angeles Capital Management & Equity Research Inc. raised its stake in Colgate-Palmolive by 405.4% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,283,928 shares of the company’s stock valued at $76,419,000 after purchasing an additional 1,029,873 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Colgate-Palmolive by 3.2% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 32,521,377 shares of the company’s stock valued at $1,935,674,000 after purchasing an additional 1,000,161 shares in the last quarter. 75.02% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently commented on CL. BNP Paribas raised Colgate-Palmolive from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $56.00 to $67.00 in a research note on Monday, February 11th. Credit Suisse Group began coverage on Colgate-Palmolive in a research note on Wednesday, March 6th. They issued an “underperform” rating for the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $61.00 price target on shares of Colgate-Palmolive in a research note on Friday, February 1st. Zacks Investment Research raised Colgate-Palmolive from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 11th. Finally, Wells Fargo & Co reaffirmed a “hold” rating and issued a $57.00 price target on shares of Colgate-Palmolive in a research note on Thursday, January 31st. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have assigned a buy rating to the company. Colgate-Palmolive has an average rating of “Hold” and a consensus target price of $65.13.
Colgate-Palmolive (NYSE:CL) last issued its earnings results on Friday, January 25th. The company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.78 billion. Colgate-Palmolive had a return on equity of 25,268.29% and a net margin of 15.44%. The business’s quarterly revenue was down 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.75 earnings per share. On average, sell-side analysts predict that Colgate-Palmolive will post 2.83 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th will be paid a dividend of $0.43 per share. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 2.60%. Colgate-Palmolive’s payout ratio is presently 56.57%.
In other Colgate-Palmolive news, SVP John J. Huston sold 1,512 shares of the business’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $66.29, for a total transaction of $100,230.48. Following the completion of the transaction, the senior vice president now owns 75,180 shares of the company’s stock, valued at $4,983,682.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John T. Cahill sold 5,780 shares of the business’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $64.46, for a total value of $372,578.80. Following the sale, the director now owns 27,820 shares in the company, valued at $1,793,277.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,700 shares of company stock valued at $3,419,284. Insiders own 1.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.themarketsdaily.com/2019/03/15/epoch-investment-partners-inc-reduces-stake-in-colgate-palmolive-cl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.